NCT04678466
No Longer Available
Not Applicable
An Expanded Access Program Providing Flotetuzumab in the Treatment of Acute Myeloid Leukemia Patients in Single, Individually-approved Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute Myeloid Leukemia
- Sponsor
- MacroGenics
- Status
- No Longer Available
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of the Expanded Access program is to provide flotetuzumab to patients with acute myeloid leukemia (AML) for whom potential benefit justifies potential treatment risks.
Detailed Description
MacroGenics will consider, on a case-by-case basis, requests by treating physicians to file a single patient investigational new drug application for expanded access to flotetuzumab and for MacroGenics to supply flotetuzumab for single patient use.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Weight of at least 17 kilograms
- •CD123-positive hematologic malignancy
- •Adequate organ reserve
- •Provider and site are trained on study protocol using flotetuzumab
Exclusion Criteria
- •AML that meets inclusion criteria for study CP-MGD006-01 (NCT02152956)
- •Primary induction failure
- •Early relapse (less than 6 months after first complete remission )
- •Three prior lines of therapy, including maximum of 1 prior salvage attempts
Outcomes
Primary Outcomes
Not specified
Similar Trials
No Longer Available
Not Applicable
Early Patient Access Treatment Use Protocol CA204-220Multiple MyelomaNCT02856438Bristol-Myers Squibb
No Longer Available
Not Applicable
Expanded Access Treatment Protocol CA204-143Multiple MyelomaNCT02368301Bristol-Myers Squibb
Available
Not Applicable
Expanded Access to Telisotuzumab VedotinNon-Small Cell Lung Cancer (NSCLC)NCT04830202AbbVie
Approved For Marketing
Not Applicable
Margetuximab Expanded Access ProgramNCT03133988TerSera Therapeutics LLC
Available
Not Applicable
A Cohort IND Expanded Access Program for Supporting Patient Access to TebentafuspUveal MelanomaNCT04960891Immunocore Ltd